IP Library Granted Patent US 8,841,333
Granted Patent B2
US 8,841,333 · App. 11/429,734 · Granted Sep 23, 2014

Methods for treating nephrolithiasis

Inventor: Nancy Joseph-Ridge (Highwood, IL)
Assignee: Takeda Pharmaceuticals U.S.A., Inc.
A61K31/415A61K31/426
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,841,333
App. No.
11/429,734
Granted
Sep 23, 2014
Kind
B2
Abstract

The present invention relates to methods of treating subjects suffering from nephrolithiasis by administering to a subject in need of treatment thereof a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof.

Claims (4)

1. A method for treating nephrolithiasis in a subject in need of treatment thereof, the method comprising the step of:

administering to the subject a therapeutically effective amount of at least one compound, wherein said at least one compound is a xanthine oxidoreductase inhibitor or a pharmaceutically acceptable salt thereof, wherein the xanthine oxidoreductase does not contain a purine ring in its structure, wherein the xanthine oxidoreductase inhibitor is 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and, wherein the therapeutically effective amount is from about 5 mg to about 300 mg.

2. A method for reducing the number of incidence of kidney stone attacks in a subject having a history of nephrolithiasis, the method of comprising the step of:

administering to the subject a therapeutically effective amount of a compound wherein said at least one compound is a xanthine oxidoreductase inhibitor or a pharmaceutically acceptable salt thereof, wherein the xanthine oxidoreductase inhibitor is 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and, wherein the therapeutically effective amount is from about 5 mg to about 300 mg.

Assignments (3)
CHANGE OF NAME Recorded Apr 2, 2012
From: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.,
To: TAKEDA PHARMACEUTICALS U.S.A., INC.
Reel/Frame 027971/0541 →
MERGER Recorded Sep 17, 2010
From: TAP PHARMACEUTICAL PRODUCTS, INC.
To: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.
Reel/Frame 025003/0201 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2006
From: JOSEPH-RIDGE, NANCY
To: TAP PHARMACEUTICAL PRODUCTS, INC.
Reel/Frame 017856/0895 →
Continuity (2)
Provisional Application 60678987 · May 9, 2005
Related Publication 20060252808A1 · Nov 9, 2006